Recent years have seen major advances in precision medicine, with diagnostic tests increasingly able to provide sophisticated genomic information to drive selection of therapies for cancers, heart disease, rheumatoid arthritis, and other complex conditions. Laboratories and payers, government and private, are exploring new models for evaluating promising new tests for coverage while they continue to generate clinical utility data. This panel will explore trends in payers’ evaluation of evidence to support coverage for precision diagnostics. Panel members will have deep experience from public and private payers and academia in generating evidence. Particular attention will be paid to the growth of the “coverage with evidence development” model of covering tests while collecting additional clinical utility data. Discussion will focus on the Medicare’s CED and Palmetto’s MolDX program as well as a new evidence development collaboration between CareFirst and Exosome Diagnostics.

Ability Level: All

Session ID: 21020